Novo Nordisk’s Wegovy Achieves Weight-Loss of 20.7% at Higher Dose, Study Says
Novo Nordisk said patients taking a bigger dose of its blockbuster obesity drug lost more weight than those on a lower dose, ...
STAT11h
High-dose Wegovy leads to substantial weight loss in trial, but falls short of Zepbound
A high dose of Novo Nordisk’s obesity drug Wegovy led patients to lose substantial weight in a clinical trial, but still less ...
Why Viking Therapeutics Stock Popped, but Novo Nordisk and Hims & Hers Health Dropped Today
In other news, Novo Nordisk announced the results from its phase 3b STEP UP semaglutide trial today. Specifically, the ...
Wegovy at Higher Dose Achieves Greater Weight Loss in Trial
Novo Nordisk said patients taking a bigger dose of its blockbuster obesity drug lost more weight than those on a lower dose, ...
These Stocks Are Moving the Most Today: Apple, Qorvo, Novo Nordisk, SLB, J.B. Hunt, Rivian, Cloudflare, and More
Stocks rallied sharply Friday and the S&P 500 was on pace for its best week since early November.These stocks were making ...
Novo Nordisk: Excellent Opportunity To Buy The Dip
Novo Nordisk's financial strength is evident through its 74% historical average ROIC and 85% gross margin. See why I rate NVO ...
Investing2d
Novo Nordisk's valuation now more attractive: Bernstein
Investing.com -- Bernstein analysts highlighted a more attractive valuation for Novo Nordisk (NYSE: NVO) following recent ...
Wider benefits of Ozempic, Wegovy put pressure on Canadian insurers to expand drug coverage
Canadian public and private insurers have balked at covering certain medication for weight-loss, but that might change as the ...